| PERIOD ENDING | 31-Mar-02 | | Total Revenue | 604,000 | | Cost of Revenue | 611,500 | | | Gross Profit | (7,500) | | | Operating Expenses | | Research Development |
-
| | Selling General and Administrative | 36,800 | | Non Recurring | (600) | | Others | 40,700 | | | | Total Operating Expenses |
-
| | | | Operating Income or Loss | (84,400) | | | Income from Continuing Operations | | Total Other Income/Expenses Net | (6,900) | | Earnings Before Interest And Taxes | (91,300) | | Interest Expense | 14,900 | | Income Before Tax | (106,200) | | Income Tax Expense | (53,000) | | Minority Interest |
-
| | | | Net Income From Continuing Ops | (53,200) | | | Non-recurring Events | | Discontinued Operations |
-
| | Extraordinary Items |
-
| | Effect Of Accounting Changes |
-
| | Other Items |
-
| | | | Net Income | (53,200) | | Preferred Stock And Other Adjustments |
-
| | | Net Income Applicable To Common Shares | ($53,200) |
|
0.51% Nasdaq 
Income Statement
